Nuno Rocha Pereira^*, Paulo Andrade, Laura Sá, Cândida Abreu, Rita Figueiredo, Roberto Silva, António Sarmento

Show more
Infectious Diseases Department, Centro Hospitalar S?o Jo?o and Faculty of Medicine of Porto University, Porto, Portugal.
Neuro- radiology Department, Centro Hospitalar S?o Jo?o, Porto, Portugal.
Pathology Department, Centro Hospitalar S?o Jo?o and Faculty of Medicine of Porto University, Porto, Portugal.
Show less

Abstract: A 54-year-old diabetic male, with idiopathic CD4 + lymphocytopenia, was presented with a two-month history of headache and periocular pain followed by vertigo, left hypoacusia and left peripheral facial palsy and hypoesthesia. More than a month after admission, a palate ulcer appeared and Infectious Diseases consultation was required. Mucormycosis was suspected and the diagnosis was confirmed by histologic examination. Despite early surgery and combination antifungal therapy, the patient did not survive. This case report illustrates the difficulty in diagnosing a rare condition with non-specific clinical manifestations and underlines the importance of a timely multidisciplinary approach in order to recognise this highly fatal disease earlier. It also describes a previously non-reported situation of mucormycosis in a patient with idiopathic CD4 + lymphocytopenia.

Keywords: Mucormycosis; Idiopathic CD4 + Lymphocytopenia; Diabetes; Amphotericin B

Cite this paper: N. Pereira, P. Andrade, L. Sá, C. Abreu, R. Figueiredo, R. Silva and A. Sarmento, "Rhino-Orbito-Cerebral Mucormycosis in a Diabetic Patient with Idiopathic CD4 + Lymphocytopenia," Advances in Infectious Diseases, Vol. 3 No. 4, 2013, pp. 248-252. doi: 10.4236/aid.2013.34037.

References

[1]   G. Petrikkos, A. Skiada, O. Lortholary, E. Roilides, T. J. Walsh and D. P. Kontoyiannis, “Epidemiology and Clinical Manifestations of Mucormycosis,” Clinical Infectious Diseases, Vol. 54, No. S1, 2012, pp. S23-S34.
http://dx.doi.org/10.1093/cid/cir866

[2]   M. N. Gamaletsou, N. V. Sipsas, E. Roilides and T. J. Walsh, “Rhino-Orbital-Cerebral Mucormycosis,” Current Infectious Disease Reports, Vol. 14, No. 4, 2012, pp. 423434.
http://dx.doi.org/10.1007/s11908-012-0272-6

[3]   J. G. Cortez, A. Speidel, C. Peixoto, E. Selicka, C. Valente, P. Figueiredo and A. Vieira, “Mind the Gap: Management of an Emergent and Threatening Invasive Fungal Infection—A Case Report of Rhino-Orbital-Cerebral and Pulmonary Mucormycosis,” Medical Mycology Case Reports, Vol. 2, 2013, pp. 79-84.
http://dx.doi.org/10.1016/j.mmcr.2013.02.008

[4]   V. Oliveira and A. Costa, “Cerebral Hematoma Caused by Mucormycosis,” Revista de Neurología, Vol. 33, No. 10, 2001, pp. 951-953.

[5]   D. S. Marques, C. Pinho Vaz, R. Branca, et al., “Rhizomucor and Scedosporium Infection Post Hematopoietic Stem-Cell Transplant,” Case Reports in Medicine, Vol. 2011, 2011, Article ID: 830769.

[6]   M. M. Roden, T. E. Zaoutis, W. L. Buchanan, et al., “Epidemiology and Outcome of Zygomycosis: A Review of 929 Reported Cases,” Clinical Infectious Diseases, Vol. 41, No. 5, 2005, pp. 634-653.
http://dx.doi.org/10.1086/432579

[7]   B. Rammaert, F. Lanternier, S. Poiree, R. Kania and O. Lortholary, “Diabetes and Mucormycosis: A Complex Interplay,” Diabetes & Metabolism, Vol. 38, No. 3, 2012, pp. 193-204.
http://dx.doi.org/10.1016/j.diabet.2012.01.002

[8]   U. Wali, A. Balkhair and A. Al-Mujaini, “Cerebro-Rhino Orbital Mucormycosis: An Update,” The Journal of Infection and Public Health, Vol. 5, No. 2, 2012, pp. 116126.
http://dx.doi.org/10.1016/j.jiph.2012.01.003

[9]   S. M. Trifilio, C. L. Bennett, P. R. Yarnold, et al., “Breakthrough Zygomycosis after Voriconazole Administration among Patients with Hematologic Malignancies Who Receive Hematopoietic Stem-Cell Transplants or Intensive Chemotherapy,” Bone Marrow Transplant, Vol. 39, No. 7, 2007, pp. 425-429.
http://dx.doi.org/10.1038/sj.bmt.1705614

[10]   D. P. Kontoyiannis, M. S. Lionakis, R. E. Lewis, et al., “Zygomycosis in a Tertiary-Care Cancer Center in the Era of Aspergillus-Active Antifungal Therapy: A CaseControl Observational Study of 27 Recent Cases,” The Journal of Infectious Diseases, Vol. 191, No. 8, 2005, pp. 1350-1360.
http://dx.doi.org/10.1086/428780

[11]   L. Pagano, B. Gleissner, L. Fianchi, “Breakthrough Zygomycosis and Voriconazole,” The Journal of Infectious Diseases, Vol. 192, No. 8, 2005, pp. 1496-1497.
http://dx.doi.org/10.1086/444433

[12]   L. Luo and T. Li, “Idiopathic CD4 Lymphocytopenia and Opportunistic Infection—An Update,” FEMS Immunology and Medical Microbiology, Vol. 54, No. 3, 2008, pp. 283-289.
http://dx.doi.org/10.1111/j.1574-695X.2008.00490.x

[13]   S. Antinori, M. Nebuloni, C. Magni, et al., “Trends in the Postmortem Diagnosis of Opportunistic Invasive Fungal Infections in Patients with AIDS: A Retrospective Study of 1630 Autopsies Performed between 1984 and 2002,” American Journal of Clinical Pathology, Vol. 132, No. 2, 2009, pp. 221-227.
http://dx.doi.org/10.1309/AJCPRAAE8LZ7DTNE

[14]   L. Nichols, R. Z. Ocque and I. Daly, “Zygomycosis Associated with HIV Infection and Liver Transplantation,” Pathology Research International, Vol. 2011, 2011, Article ID: 545981.

[15]   H. Y. Sun and N. Singh, “Mucormycosis: Its Contemporary Face and Management Strategies,” The Lancet Infectious Diseases, Vol. 11, No. 4, 2011, pp. 301-311.
http://dx.doi.org/10.1016/S1473-3099(10)70316-9

[16]   T. J. Walsh, M. N. Gamaletsou, M. R. McGinnis, R. T. Hayden and D. P. Kontoyiannis, “Early Clinical and Laboratory Diagnosis of Invasive Pulmonary, Extrapulmonary, and Disseminated Mucormycosis (Zygomycosis),” Clinical Infectious Diseases, Vol. 54, No. S1, 2012, pp. S55-S60.
http://dx.doi.org/10.1093/cid/cir868

[17]   B. Spellberg, A. Ibrahim, E. Roilides, et al., “Combination Therapy for Mucormycosis: Why, What, and How?” Clinical Infectious Diseases, Vol. 54, No. S1, 2012, pp. S73-S78.
http://dx.doi.org/10.1093/cid/cir885

[18]   C. Reed, R. Bryant, A. S. Ibrahim, et al., “Combination Polyene-Caspofungin Treatment of Rhino-Orbital-Cerebral Mucormycosis,” Clinical Infectious Diseases, Vol. 47, No. 3, 2008, pp. 364-371.
http://dx.doi.org/10.1086/589857

[19]   A. Tragiannidis and A. H. Groll, “Hyperbaric Oxygen Therapy and Other Adjunctive Treatments for Zygomycosis,” Clinical Microbiology and Infection, Vol. 15, No. S5, 2009, pp. 82-86.
http://dx.doi.org/10.1111/j.1469-0691.2009.02986.x

[20]   A. Safdar, “Immunotherapy for Invasive Mold Disease in Severely Immunosuppressed Patients,” Clinical Infectious Diseases, Vol. 57, No. 1, 2013, pp. 94-100.
http://dx.doi.org/10.1093/cid/cit187